Dr Xiao Jun Wang

Dr Xiao Jun Wang

Dr Xiao Jun (Nick) Wang is a health economist and health technology assessment (HTA) specialist with over 10 years of experience spanning academia, government, and the industry across Singapore, Malaysia, Canada, and the broader Asia-Pacific region. Dr Wang holds a PhD in Health Economics from the National University of Singapore (NUS) and began his HTA career as a Senior Health Technology Assessment Analyst at the Agency for Care Effectiveness (ACE), Ministry of Health Singapore, where he specialised in the evaluation of medical devices and diagnostics for government subsidy decision-making. Following his government tenure, Dr Wang transitioned to senior Market Access and Value leadership roles in the pharmaceutical industry, including at Novartis Singapore and Amgen Singapore and Malaysia, where he led HTA dossier preparation, evidence generation, and reimbursement strategy for a broad range of innovative therapies, including the first successful Cell and Gene Therapy reimbursement approvals in Singapore. He has also contributed to HTA processes in Canada through submissions to Canada’s Drug Agency.

Dr Wang has authored over 20 peer-reviewed publications in health economics and outcomes research, with work presented at major international conferences including ISPOR and HTAi. He is also actively engaged in health economics education at the postgraduate level.